Chinese clinical stage biotechnology company InventisBio Inc. announced on Monday the closing of a US$70 million series C round of financing led by Chinese private equity firm Advantech Capital and CMB International Capital, a wholly-owned subsidiary of China Merchants Bank (CMB).
UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Read 2 Articles for Free with a Basic Account
Gain limited and restricted access to China Money Network.
Register Basic AccountSubscribe for an annual subscription!
Enjoy comprehensive and exclusive data you can't find elsewhere!
More Info
Already have an account or paid subscription? Log in
